Dna vaccine against tumor growth and methods of use thereof
CA 2519953 C · Owner: The Scripps Research Institute · Inventors: Reisfeld, Ralph A.; Xiang, Rong; Zhou, He
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product such as a cytokine , or a ligand for a natural killer cell surface receptor in a pharmaceutically , acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA human MICB, human , ULBP1, human ULBP2 and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 24, 2004 and granted January 5, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 24, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 24, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.